文献速递胸部肿瘤

SKYSCRAPER-02:替瑞利尤单抗联合阿替利珠单抗加化疗治疗未经治疗的广泛期小细胞肺癌

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2023-11-17

III期SKYSCRAPER-02研究评估在阿替利珠单抗+卡铂+依托泊苷(CE)基础上加用替瑞利尤单抗能否增效。无脑转移患者中,PFS和OS均未达统计学显著,替瑞利尤单抗组中位PFS 5.4个月 vs 对照组5.6个月(分层HR 1.11,P=0.3504),两组中位OS均为13.1个月(分层HR 1.14,P=0.2859)。结论:替瑞利尤单抗未提供额外获益,联合方案耐受性良好,无新安全信号。

要点

  • 在未经治疗的广泛期小细胞肺癌中,替瑞利尤单抗联合阿替利珠单抗+CE未改善PFS或OS。
  • 无脑转移患者中位PFS:替瑞利尤单抗组5.4个月 vs 对照组5.6个月(分层HR 1.11,P=0.3504)。
  • 两组中位OS均为13.1个月(分层HR 1.14,P=0.2859)。

核心结论

  • 在未经治疗的广泛期小细胞肺癌中,替瑞利尤单抗联合阿替利珠单抗和CE未较阿替利珠单抗+CE提供额外获益。
  • 联合方案耐受性良好,未观察到新的安全信号。

研究设计与样本

  • III期SKYSCRAPER-02研究。
  • 患者随机接受替瑞利尤单抗600 mg或安慰剂,联合阿替利珠单抗1,200 mg和CE(4个周期),随后维持替瑞利尤单抗/安慰剂联合阿替利珠单抗。
  • 主要终点为无脑转移史/无脑转移患者的研究者评估PFS和OS(主要分析集[PAS])。
  • 全分析集(FAS)共490例患者随机分配:替瑞利尤单抗组243例,对照组247例。

主要发现

  • PAS(n=397)最终PFS分析未达统计学显著:分层HR 1.11,P=0.3504;中位PFS替瑞利尤单抗组5.4个月 vs 对照组5.6个月。
  • 数据截止2022年2月6日,中位随访时间PAS为14.3个月、FAS为13.9个月。
  • 数据截止2022年9月6日,FAS中位随访21.2个月,PAS最终OS分析两组中位OS均为13.1个月(分层HR 1.14,P=0.2859)。
  • FAS中位PFS和OS与PAS一致。
  • 免疫介导不良事件发生率:替瑞利尤单抗组54.4% vs 对照组49.2%(3/4级:7.9% vs 7.7%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung cancer (ES-SCLC). We report final progression-free survival (PFS) and overall survival (OS) analyses. METHODS: Patients received tiragolumab 600 mg/placebo, plus atezolizumab 1,200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab. Primary end points were investigator-assessed PFS and OS in patients without history/presence of brain metastases (primary analysis set [PAS]). Additional end points included PFS and OS in all patients regardless of brain metastases status (full analysis set [FAS]), response, and safety. RESULTS: Four hundred ninety patients were randomly assigned (FAS): 243 to tiragolumab arm and 247 to control arm. At the cutoff date (February 6, 2022; median duration of follow-up, 14.3 months [PAS] and 13.9 months [FAS]), final analysis of PFS in the PAS (n = 397) did not reach statistical significance (stratified hazard ratio [HR], 1.11; P = .3504; median, 5.4 months tiragolumab v 5.6 months control). At the cutoff date (September 6, 2022; median duration of follow-up, 21.2 months [FAS]), median OS in the PAS at final OS analysis was 13.1 months in both arms (stratified HR, 1.14; P = .2859). Median PFS and OS in the FAS were consistent with the PAS. The proportion of patients with immune-mediated adverse events (AEs) in the tiragolumab and control arms was 54.4% and 49.2%, respectively (grade 3/4: 7.9% and 7.7%). AEs leading to treatment withdrawal occurred in 8.4% and 9.3% of tiragolumab- and control-treated patients, respectively. CONCLUSION: Tiragolumab did not provide additional benefit over atezolizumab and CE in untreated ES-SCLC. The combination was well tolerated with no new safety signals.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rudin CM, Liu SV, Soo RA, et al. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 37976444. doi:10.1200/JCO.23.01363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。